Lung Cancer Clinical Trials in Phoenix

Showing 141-160 of 278 trials

A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers

NCT04025216

Multi-center, open-label, first in human Phase 1 study of the safety, tolerability, feasibility, and preliminary efficacy of the administration of genetically modified autologous T cells (CART-TnMUC1 cells) engineered to express a chimeric antigen receptor (CAR) capable of recognizing the tumor antigen, TnMUC1 and activating the T cell (CART- TnMUC1 cells).

Non-Small Cell Lung CancerOvarian CancerFallopian Tube Cancer+3 more

Kite, A Gilead Company16 participantsStarted Oct 2019

Phoenix, Arizona, United States • Los Angeles, California, United States • Tampa, Florida, United States +7 more locations

COMPLETEDPHASE1/PHASE2< 1 mile

A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab

NCT03409458

This is a Phase 1/2, open-label, multi-center, non-randomized, dose-escalation study of PT-112 in combination with the anti-PD-L1 antibody, avelumab, in selected advanced solid tumors. The study is to be conducted in two parts: the Dose Escalation Phase of PT-112 within the combination and the Dose Confirmation Phase in patients with non-small cell lung cancer who will be treated at the RP2D.

Non-Small Cell Lung Cancer (NSCLC)

Promontory Therapeutics Inc.68 participantsStarted Apr 2018

Phoenix, Arizona, United States • Aurora, Colorado, United States • Jacksonville, Florida, United States +3 more locations

A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers

A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab

Lung Cancer Trials in Other Cities

Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors

A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents

A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer

A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)

A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)

Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations

Survival Prolongation by Rationale Innovative Genomics

Study of PF-07263689 in Participants With Selected Advanced Solid Tumors

Study of the CD40 Agonistic Monoclonal Antibody APX005M

Phase I/IIa Study of H002 in NSCLC With Active EGFR Mutation

A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors

An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors

OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure

Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Palliative Care Interventions for Outpatients Newly Diagnosed With Lung Cancer: Phase II

Other Conditions in Phoenix